CA3222142A1 - Enrichissement negatif-positif pour la detection d'acides nucleiques - Google Patents
Enrichissement negatif-positif pour la detection d'acides nucleiques Download PDFInfo
- Publication number
- CA3222142A1 CA3222142A1 CA3222142A CA3222142A CA3222142A1 CA 3222142 A1 CA3222142 A1 CA 3222142A1 CA 3222142 A CA3222142 A CA 3222142A CA 3222142 A CA3222142 A CA 3222142A CA 3222142 A1 CA3222142 A1 CA 3222142A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- sample
- segment
- dna
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 164
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 164
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 164
- 238000001514 detection method Methods 0.000 title description 25
- 238000000034 method Methods 0.000 claims abstract description 139
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 50
- 239000000523 sample Substances 0.000 claims description 98
- 230000035772 mutation Effects 0.000 claims description 73
- 108020005004 Guide RNA Proteins 0.000 claims description 59
- 108010042407 Endonucleases Proteins 0.000 claims description 54
- 102000004533 Endonucleases Human genes 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 108060002716 Exonuclease Proteins 0.000 claims description 24
- 102000013165 exonuclease Human genes 0.000 claims description 24
- 102000023732 binding proteins Human genes 0.000 claims description 19
- 108091008324 binding proteins Proteins 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 13
- 238000012163 sequencing technique Methods 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 11
- 230000001605 fetal effect Effects 0.000 claims description 11
- 108700028369 Alleles Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 9
- 230000008774 maternal effect Effects 0.000 claims description 9
- 238000010186 staining Methods 0.000 claims description 9
- 238000001493 electron microscopy Methods 0.000 claims description 8
- 239000007850 fluorescent dye Substances 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 8
- 230000005291 magnetic effect Effects 0.000 claims description 8
- 238000000399 optical microscopy Methods 0.000 claims description 8
- 238000002798 spectrophotometry method Methods 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 5
- 238000001502 gel electrophoresis Methods 0.000 claims description 5
- 238000011528 liquid biopsy Methods 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000007717 exclusion Effects 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 239000000696 magnetic material Substances 0.000 claims description 2
- 239000002907 paramagnetic material Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 abstract description 17
- 230000029087 digestion Effects 0.000 abstract description 16
- 238000000746 purification Methods 0.000 abstract description 4
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 99
- 239000012634 fragment Substances 0.000 description 35
- 230000004075 alteration Effects 0.000 description 23
- 210000002381 plasma Anatomy 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 230000037442 genomic alteration Effects 0.000 description 11
- 239000007795 chemical reaction product Substances 0.000 description 10
- 108091033409 CRISPR Proteins 0.000 description 9
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 9
- 101710163270 Nuclease Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 238000010362 genome editing Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000004255 ion exchange chromatography Methods 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000005945 translocation Effects 0.000 description 6
- 238000010459 TALEN Methods 0.000 description 5
- 108091093094 Glycol nucleic acid Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108091046915 Threose nucleic acid Proteins 0.000 description 4
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000005266 circulating tumour cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- -1 rRNA Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 238000005377 adsorption chromatography Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 229920001109 fluorescent polymer Polymers 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007671 third-generation sequencing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762519051P | 2017-06-13 | 2017-06-13 | |
| US62/519,051 | 2017-06-13 | ||
| US201762526091P | 2017-06-28 | 2017-06-28 | |
| US62/526,091 | 2017-06-28 | ||
| US201762568121P | 2017-10-04 | 2017-10-04 | |
| US62/568,121 | 2017-10-04 | ||
| US15/877,619 US10527608B2 (en) | 2017-06-13 | 2018-01-23 | Methods for rare event detection |
| US15/877,619 | 2018-01-23 | ||
| US201862656592P | 2018-04-12 | 2018-04-12 | |
| US62/656,592 | 2018-04-12 | ||
| CA3069934A CA3069934A1 (fr) | 2017-06-13 | 2018-06-13 | Enrichissement negatif-positif pour la detection d'acides nucleiques |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3069934A Division CA3069934A1 (fr) | 2017-06-13 | 2018-06-13 | Enrichissement negatif-positif pour la detection d'acides nucleiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3222142A1 true CA3222142A1 (fr) | 2018-12-20 |
Family
ID=64659281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3222142A Pending CA3222142A1 (fr) | 2017-06-13 | 2018-06-13 | Enrichissement negatif-positif pour la detection d'acides nucleiques |
| CA3069934A Abandoned CA3069934A1 (fr) | 2017-06-13 | 2018-06-13 | Enrichissement negatif-positif pour la detection d'acides nucleiques |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3069934A Abandoned CA3069934A1 (fr) | 2017-06-13 | 2018-06-13 | Enrichissement negatif-positif pour la detection d'acides nucleiques |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3638809A4 (fr) |
| CA (2) | CA3222142A1 (fr) |
| WO (1) | WO2018231945A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081829B1 (en) | 2017-06-13 | 2018-09-25 | Genetics Research, Llc | Detection of targeted sequence regions |
| US11384383B2 (en) | 2017-08-08 | 2022-07-12 | Depixus | In vitro isolation and enrichment of nucleic acids using site-specific nucleases |
| US20210040537A1 (en) * | 2019-08-08 | 2021-02-11 | Genetics Research, Llc | Selective enrichment |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2817990A1 (fr) * | 2009-12-23 | 2011-06-30 | Genetic Technologies Limited | Procedes d'enrichissement et de detection d'acides nucleiques foetaux |
| WO2015183025A1 (fr) * | 2014-05-28 | 2015-12-03 | 주식회사 툴젠 | Procédé permettant la détection sensible d'adn cible à l'aide d'une nucléase spécifique de cible |
| EP3633047B1 (fr) * | 2014-08-19 | 2022-12-28 | Pacific Biosciences of California, Inc. | Procédés de séquenage d' acides nucléiques basé sur un enrichissement d'acides nucléiques |
| US10421993B2 (en) * | 2015-02-11 | 2019-09-24 | Paragon Genomics, Inc. | Methods and compositions for reducing non-specific amplification products |
| WO2016134136A2 (fr) * | 2015-02-20 | 2016-08-25 | The Johns Hopkins University | Altérations génomiques dans la tumeur et circulation de patients atteints d'un cancer du pancréas |
| EP3985111A1 (fr) * | 2015-08-19 | 2022-04-20 | Arc Bio, LLC | Capture d'acides nucléiques à l'aide d'un système utilisant une nucléase guidée par des acides nucléiques |
| ES2788176T3 (es) * | 2015-09-24 | 2020-10-20 | Sigma Aldrich Co Llc | Métodos y reactivos para la detección de proximidad molecular usando proteínas de unión a ácido nucleico guiadas por ARN |
| US11384383B2 (en) * | 2017-08-08 | 2022-07-12 | Depixus | In vitro isolation and enrichment of nucleic acids using site-specific nucleases |
| US20210010065A1 (en) * | 2018-03-15 | 2021-01-14 | Twinstrand Biosciences, Inc. | Methods and reagents for enrichment of nucleic acid material for sequencing applications and other nucleic acid material interrogations |
-
2018
- 2018-06-13 CA CA3222142A patent/CA3222142A1/fr active Pending
- 2018-06-13 CA CA3069934A patent/CA3069934A1/fr not_active Abandoned
- 2018-06-13 WO PCT/US2018/037277 patent/WO2018231945A1/fr unknown
- 2018-06-13 EP EP18817717.4A patent/EP3638809A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3638809A1 (fr) | 2020-04-22 |
| CA3069934A1 (fr) | 2018-12-20 |
| EP3638809A4 (fr) | 2021-03-10 |
| WO2018231945A1 (fr) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190382824A1 (en) | Negative-positive enrichment for nucleic acid detection | |
| CN116157533A (zh) | 使用杂交方法捕获遗传靶标 | |
| US20180355409A1 (en) | Tumor mutation burden by quantification of mutations in nucleic acid | |
| US20190048425A1 (en) | Tumor detection and monitoring | |
| CA3222142A1 (fr) | Enrichissement negatif-positif pour la detection d'acides nucleiques | |
| Mathot et al. | Automated serial extraction of DNA and RNA from biobanked tissue specimens | |
| US20240052396A1 (en) | Selective protection of nucleic acids | |
| CN114752672B (zh) | 基于循环游离DNA突变进行滤泡性淋巴瘤预后评估的检测panel、试剂盒及应用 | |
| US11486003B2 (en) | Highly sensitive methods for accurate parallel quantification of nucleic acids | |
| CA3069939A1 (fr) | Detection et surveillance de tumeur | |
| US20180355437A1 (en) | Plasma/serum target enrichment | |
| US20200103399A1 (en) | Methods for rare event detection | |
| Koessler et al. | Implementing circulating tumor DNA analysis in a clinical laboratory: a user manual | |
| CN106282361B (zh) | 用于捕获血液病相关基因的基因捕获试剂盒 | |
| US20190002964A1 (en) | Bodily fluid target enrichment | |
| US20190085318A1 (en) | Solid phase negative enrichment | |
| CN111742216A (zh) | 半自动化研究仪器系统 | |
| US20210155972A1 (en) | Targeted rare allele crispr enrichment | |
| WO2022034300A1 (fr) | Analyse multiomique de couronnes de nanoparticules | |
| US20190071716A1 (en) | Bodily fluid enrichment | |
| US20240200122A1 (en) | Bodily fluid target enrichment | |
| EP4215619A1 (fr) | Procédés de quantification parallèle, sensible et précise d'acides nucléiques | |
| US20240209348A1 (en) | Solid phase negative enrichment | |
| Killian et al. | Genome-wide methylation profiling in archival formalin-fixed paraffin-embedded tissue samples | |
| Andrew et al. | Next-generation liquid biopsy: tumor monitoring from droplet volumes of blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231206 |
|
| EEER | Examination request |
Effective date: 20231206 |